# Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE

> **NCT05492799** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **Allievex Corporation** · enrollment: 15 (estimated)

## Conditions studied

- MPS III B

## Interventions

- **DRUG:** AX 250

## Key facts

- **NCT ID:** NCT05492799
- **Lead sponsor:** Allievex Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2022-12-02
- **Primary completion:** 2027-10
- **Final completion:** 2027-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2023-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05492799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05492799, "Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05492799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*